Skip to main content




Mood - Treatment Resistant Depression - Major Depressive Disorder with inadequate response to 2 or more antidepressants

Areas of Interest:

  • Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
  • TRD: early patient identification & treatment initiation
  • Primary care provider’s role in the early identification & treatment of TRD
  • Mechanistic rationale to pharmacological treatment approaches
  • Algorithmic treatment approaches in TRD including interventional psychiatry treatments
  • Early use of new antidepressants in TRD
  • Strategies for preventing relapse in TRD, and the impact of relapse prevention
  • Value of innovative treatments from the patient & societal perspective
  • Impact MDD & TRD in minoritized communities and populations

Mood – Targeting Novel Pathways In Depression

Areas of Interest:

  • Clinical correlates between unresolved, residual symptoms of Major Depressive Disorder (MDD) and underlying pathophysiology not addressed with current Standard of Care treatments
  • Early use of adjunctive strategies in the treatment of MDD in specialty and primary care setting
  • The role of Nurse Practitioners, Physician Assistants and Primary Care providers in assessment, diagnosis and management of MDD
  • Clinical and biological underpinnings of anhedonia in MDD
  • The neurobiology and neurocircuitry of motivation and reward
  • Best practices in the assessment and diagnosis of anhedonia in MDD patients
  • Clinical and neurobiological underpinnings of insomnia in MDD
  • The role of orexin system in depression
  • Clinical, humanistic and economic impact of anhedonia and/or insomnia symptoms in patients with MDD
  • Diversity, Equity and Inclusion considerations in assessment, diagnosis and management of MDD (including specific symptoms of anhedonia and/or insomnia)
  • Experience of MDD with anhedonia or insomnia by diverse patient segments

Schizophrenia - Adults with Schizophrenia

Areas of Interest:

  • Earlier adoption of long-acting injectable antipsychotics (LAI)
  • Clinical stability & persistency through advancing patients to a longer dosing interval
  • Switching oral antipsychotics to long-acting injectable antipsychotics
  • Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
  • Patient & caregiver preferences in LAI utilization
  • Patterns of antipsychotic LAI utilization in minoritized communities and populations (including social determinants of health)
  • Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
  • Antipsychotic LAI transition of care models (inpatient to outpatient)
  • Champion the destigmatization of schizophrenia to encourage compassion and acceptance

Learners of Interest

  • Nurse Practitioners
  • Early-in-Career
  • Psychiatrists
  • Primary Care
  • Patient
  • Caregiver / Care Team
  • Physician Assistants
  • Pharmacists
  • Payer
  • Advocacy Partners

Certificate Of Separation

Please click here to view the certificate of separation
Click here to submit an Independent Medical Education Grant